Imeglimin beneficial as add-on to metformin in T2DM

Imeglimin beneficial as add-on to metformin in T2DM
For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

(HealthDay)—For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.

Pascale Fouqueray, M.D., of Poxel in Lyon, France, and colleagues conducted a 12-week, phase II, randomized, controlled study involving 156 patients with type 2 diabetes who were inadequately controlled on metformin alone to assess the efficacy and safety of imeglimin as add-on therapy. Patients received a stable dose of metformin (1,500 to 2,000 mg/day) plus imeglimin (1,500 mg twice daily) or placebo.

After 12 weeks, the researchers found that the placebo-subtracted decrease in hemoglobin A1c was a significant −0.44 percent with metformin-imeglimin. Compared with metformin-placebo, metformin-imeglimin correlated with significant improvements in fasting and the proinsulin/insulin ratio from baseline. The safety profile of the metformin-imeglimin combination was similar to that of metformin-placebo, and the combination was generally well tolerated.

"This phase II study demonstrated that first-in-class imeglimin was well tolerated and effective when combined with metformin as a potential new treatment for ," the authors write.

Several authors disclosed to pharmaceutical companies, including Poxel, which primarily funded the study and manufactures imeglimin.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Lung cancer risk unaffected by metformin use in diabetes

Aug 30, 2012

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

Metformin may have dual effect in breast cancer

May 09, 2012

(HealthDay) -- For women without diabetes and with operable breast cancer, administration of metformin prior to surgery does not significantly affect the proliferative marker Ki-67 overall, but drug effects ...

Recommended for you

Single enzyme is necessary for development of diabetes

Aug 14, 2014

An enzyme called 12-LO promotes the obesity-induced oxidative stress in the pancreatic cells that leads to pre-diabetes, and diabetes. 12-LO's enzymatic action is the last step in the production of certain small molecules ...

User comments